Skip Nav Destination
Close Modal
Update search
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Article Type
Date
Availability
1-11 of 11
Keywords: cGMP
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2021) 135 (10): 1209–1212.
Published: 20 May 2021
...Anton J.M. Roks; Caroline Cheng; Catherine M. Shanahan Vascular smooth muscle biology is increasingly exploited as an interventional target in vascular disease. Vascular smooth muscle Notch3–Rho kinase–cGMP interaction has been implicated in brain and peripheral arteriopathy in CADASIL...
Articles
Roel Bijkerk, Marina A. Aleksinskaya, Jacques M.G.J. Duijs, Jennifer Veth, Bettina Husen, Dania Reiche, Cornelia Prehn, Jerzy Adamski, Ton J. Rabelink, Jo G.R. De Mey, Anton Jan van Zonneveld
Journal:
Clinical Science
Clin Sci (Lond) (2019) 133 (2): 239–252.
Published: 22 January 2019
... by excessive accumulation of myofibroblast-derived extracellular matrix. Natriuretic peptides have been demonstrated to have cyclic guanosine monophosphate (cGMP)-dependent anti-fibrotic properties likely due to interference with pro-fibrotic tissue growth factor β (TGF-β) signaling. However, in vivo...
Includes: Supplementary data
Articles
Angelika Hammerer-Lercher, Johann Fersterer, Sigrid Holzmann, Johannes Bonatti, Elfriede Ruttmann, Daniel Hoefer, Johannes Mair, Bernd Puschendorf
Journal:
Clinical Science
Clin Sci (Lond) (2006) 111 (3): 225–231.
Published: 15 August 2006
...) and the NO (nitric oxide) donor sin-1 (3-morpholino-sydnonimine) in human by-pass grafts. In contrast with previous studies, the same vessel was used to demonstrate a direct link between cGMP production and functional relaxation. Remnants of the IMA (internal mammary artery) and SV (saphenous vein) were obtained...
Articles
Takashi YAMAMOTO, Atsuyuki WADA, Masato OHNISHI, Takayoshi TSUTAMOTO, Masanori FUJII, Takehiro MATSUMOTO, Tomoyuki TAKAYAMA, Xinwen WANG, Kiyoshi KUROKAWA, Masahiko KINOSHITA
Journal:
Clinical Science
Clin Sci (Lond) (2002) 103 (s2002): 258S–262S.
Published: 01 September 2002
... in congestive heart failure (CHF). Renal production of ET-1 increases in CHF and it is a significant independent predictor of sodium excretion. ANP inhibits the ET system through cGMP, a second messenger of ANP. However, in severe CHF, plasma cGMP levels reached a plateau despite the activation of ANP secretion...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2002) 102 (2): 213–222.
Published: 14 January 2002
... suggests that inducible NO synthase attenuates ventricular contractility, mediated by cGMP. Another gas that transduces its signal through cGMP, carbon monoxide, is also likely to play a role in cirrhotic cardiomyopathy, but the nature of the interaction between NO and carbon monoxide in this syndrome...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2001) 100 (5): 473–479.
Published: 29 March 2001
... μ M), supporting the role of NO in maintenance of basal relaxation and vascular tone in females. We have examined the relative activity of the specific PKG subtypes 1α and 1β in vascular smooth muscle, based on relaxation of rat aortas by two cGMP analogues with different selectivity, β-phenyl-l- N...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2000) 99 (4): 255–260.
Published: 06 September 2000
... tissue levels of cGMP, and that could be beneficial for the treatment of cardiovascular conditions. Starting from zaprinast, a weak phosphodiesterase inhibitor, computer modelling guided rational medicinal chemistry to achieve significant increases in potency and selectivity for the 5-isoenzyme within...
Articles
T. FORST, D. DUFAYET DE LA TOUR, T. KUNT, A. PFÜTZNER, K. GOITOM, T. POHLMANN, S. SCHNEIDER, B. L. JOHANSSON, J. WAHREN, M. LÖBIG, M. ENGELBACH, J. BEYER, P. VAGUE
Journal:
Clinical Science
Clin Sci (Lond) (2000) 98 (3): 283–290.
Published: 09 February 2000
... for 60 min, and thereafter at 10 pmol·min -1 ·kg -1 for 60 min. At baseline and after 60 and 120 min, laser Doppler flow (LDF) was measured following acetylcholine iontophoresis or mild thermal stimulation (44 °C), and venous blood samples were collected to determine plasma cGMP levels and erythrocyte...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (2000) 98 (1): 81–89.
Published: 29 November 1999
... and CA were studied. Tissue cGMP levels were measured in the absence and presence of l -NAME, ODQ, 5-HT and U46619. 5-HT was approximately 30 times more potent in SA {-log [EC 50 (M)] (pEC 50 ) 6.32±0.13} than in CA (5.05±0.14). U46619 displayed a similar potency in both CA (pEC 50 7.80±0.07) and SA...
Articles
Journal:
Clinical Science
Clin Sci (Lond) (1996) 91 (2): 225–231.
Published: 01 August 1996
... if inhaled nitric oxide influences platelet function in vivo in healthy subjects. 2. Platelet aggregability (filtragometry ex vivo , which reflects aggregability in vivo ), bleeding time and platelet secretion products and cGMP in plasma were studied during inhalation of two different doses of nitric oxide...
Articles
Yasunobu Hirata, Yasuko Suzuki, Hiroshi Hayakawa, Etsu Suzuki, Kenjiro Kimura, Atsuo Goto, Kenji Kangawa, Hisayuki Matsuo, Masao Omata
Journal:
Clinical Science
Clin Sci (Lond) (1995) 88 (4): 413–419.
Published: 01 April 1995
... in glomerular filtration rate (−32 ± 11%, P < 0.05) and urinary cGMP excretion (−40 ± 14%, P < 0.05). No significant effects of HS-42-1 on renal function were observed in control rats. 6. These results suggest that elevated plasma glucose may lead to an increase in atrial natriuretic peptide secretion via...